“IS THERE A ROLE FOR MINIMAL RESIDUAL DISEASE MONITORING IN FOLLICULAR LYMPHOMA IN THE CHEMO-IMMUNOTHERAPY ERA?”, Mediterr J Hematol Infect Dis, vol. 9, no. 1, p. e2017010, Jan. 2017, doi: 10.4084/mjhid.2017.010.